Makale Koleksiyonu
Bu koleksiyon için kalıcı URI
Güncel Gönderiler
Öğe Bir Deneyimi Unutulmaz Kılan Unsurlar Nedir? Unutulmaz Turizm Deneyimi Üzerine Kavramsal Bir Değerlendirme(Trakya Üniversitesi, 2019) Demir, Seda; Ülker Demirel, ElifGünümüzün küreselpazarında rekabet gün geçtikçe artmakta, rekabet avantajı elde etmekzorlaşmaktadır. Hızlı değişim ve yeniliklerin yaşandığı günümüzde işletmeler bugelişmelere ayak uydurmak durumundadır. Zira günümüz tüketicisi için nihai üründen ziyade, yaşanılan ürün vehizmet deneyimi satın alma karar sürecinde belirleyici hale gelmektedir. Bunoktada taklit edilmesi, ikamesi zor olan ve tüketiciler tarafından arzuedilen, onların beklentilerine cevap verebilen deneyimsel ortamlarınyaratılması rekabet avantajı açısından oldukça önem arz etmektedir. Ancak dünyadave turist profilinde meydana gelen gelişmeler ve değişiklikler, turistlerinbeklentilerinin de farklılaşmasına neden olmaktadır. Turistlerin ihtiyaçlarınıngiderilmesi dışında farklılık arayışı, kendini değerli hissetme, yenilenme,yeni kültürler ve insanlar tanıma gibi benzersiz deneyimler yaşamaya yönelikeğilimleri, bir deneyimi eşsiz ve unutulmaz kılan unsurlar üzerineodaklanılmasına sebebiyet vermektedir. Literatür incelendiğinde tüketici,ziyaretçi, turist ve seyahat deneyimi üzerine çok sayıda çalışmanın yer aldığıgörülmekle birlikte, “Unutulmaz Turizm Deneyimi” kavramı bu alanda oldukça yenibir araştırma konusu olarak yer almaktadır. Bu kavramla ilgili yabancı literatürdeki çalışmalarincelendiğinde bir literatür birikiminin oluştuğunu belirtmek mümkün olmaktaancak, yerli literatürde oldukça sınırlı sayıda çalışmanın yer aldığıgörülmektedir. Dolayısıyla bu çalışmanın amacı, uluslararası ve ulusal literatürün kapsamlı birdeğerlendirmesini yaparak mevcut akademik yazına katkıda bulunmak ve yeni birkavram olan unutulmaz turizm deneyimi olgusunu kapsam ve içerik açısındandeğerlendirmektir. Bu anlamda söz konusu bulguların ve değerlendirmelerin turizmişletmecilerine ve destinasyon yöneticilerine, turistlerin karar vermesüreçlerinde göz önünde bulundurdukları unsurların anlaşılması açısından yolgöstereceği öngörülmektedir.Öğe Precise and Immediate Action against Predatory Conferences(2020) Koçak, Zafer[Abtract Not Available]Öğe Solitary Fibrous Tumors of Chest: Another Look with the Oncologic Perspective(2017) Saynak, Mert; Veeramachaneni, Nirmal K.; Hubbs, Jessica L.; Okumuş, Dilruba; Marks, Lawrence B.Solitary fibrous tumors are mesenchymal lesions that arise at a variety of sites, most commonly the pleura. Most patients are asymptomatic at diagnosis, with lesions being detected incidentally. Nevertheless, some patients present due to symptoms from local tumor compression (eg. of the airways and pulmonary parenchyma). Furthermore, radiological methods are not always conclusive in making a diagnosis, and thus, pathological analysis is often required. In the past three decades, immunohistochemical techniques have provided a gold standard in solitary fibrous tumor diagnosis. The signature marker of solitary fibrous tumor is the presence of the NAB2-STAT6 fusion that can be reliably detected with a STAT6 antibody. While solitary fibrous tumors are most often benign, they can be malignant in 10-20% of the cases. Unfortunately, histological parameters are not always predictive of benign vs malignant solitary fibrous tumors. As solitary fibrous tumors are generally regarded as relatively chemoresistant tumors; treatment is often limited to localized treatment modalities. The optimal treatment of solitary fibrous tumors appears to be complete surgical resection for both primary and local recurrent disease. However, in cases of suboptimal resection, large disease burden, or advanced recurrence, a multidisciplinary approach may be preferable. Specifically, radiotherapy for inoperable local disease can provide palliation/shrinkage. Given their sometimes -unpredictable and often- protracted clinical course, long-term follow-up post-resection is recommended.Öğe Announcing the New Website of Balkan Medical Journal(2017) Koçak, Zafer; Karadağ, Çetin HakanAt the end of the last year, we, editorial team, decided to redesign our website to better serve our readers, reviewers and authors. After much hard work, we are excited to officially announce the new and improved Balkan Medical Journal website. You can now reach us at http://balkanmedicaljournal.org/ We thought that it was important to renew the website to reacha wider audience. So, we wanted to have good, clear, easy-tofollow navigation throughout our website. The new website will remain both open access and free of article processing charges.We hope that the website will respond better to our readers'needs and interests.Öğe KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer(2016) Kodaz, Hilmi; Taştekin, Ebru; Erdoğan, Bülent; Hacıbekiroğlu, İlhan; Tozkır, Hilmi; Gürkan, Hakan; Çiçin, İrfanBackground: Lung cancer is one of the most lethal cancers. It is mainly classified into 2 groups: non-small cell lung can-cer (NSCLC) and small cell lung cancer (SCLC). Extrapul-monary small cell carcinomas (EPSCC) are very rare. The Ras oncogene controls most of the cellular functions in the cell. Overall, 21.6% of human cancers contain a Kirsten Ras (KRAS) mutation. SCLC and EPSCC have several similar features but their clinical course is different.Aims: We investigated the KRAS mutation status in SCLC and EPSCC.Study design: Mutation research.Methods: Thirty-seven SCLC and 15 EPSCC patients were included in the study. The pathological diagnoses were confirmed by a second pathologist. KRAS analysis was performed in our medical genetic department. DNA isola-tion was performed with primary tumor tissue using the QIAamp DNA FFPE Tissue kit (Qiagen; Hilden, Germany) in all patients. The therascreen KRAS Pyro Kit 24 V1 (Qia-gen; Hilden, Germany) was used for KRAS analyses. Results: Thirty-four (91.9%) of the SCLC patients were male, while 11 (73.3%) of the EPSCC l patients were fe-male. SCLC was more common in males, and EPSCC in females (p=0.001). A KRAS mutation was found in 6 (16.2%) if SCLC patients. The most common mutation was Q61R (CAA>CGA). Among the 15 EPSCC patients, 2 had a KRAS mutation (13.3%). When KRAS mutant and wild type patients were compared in the SCLC group, no differ-ence was found for overall survival (p=0.6).Conclusion: In previous studies, the incidence of KRAS mutation in SCLC was 1-3%; however, it was 16.2% in our study. Therefore, there may be ethnic and geographical differences in the KRAS mutations of SCLC. As a result, KRAS mutation should not be excluded in SCLCÖğe Predictive and Prognostic Factors in Ovarian and Uterine Carcinosarcomas(2016) Çiçin, İrfan; Özatlı, Tahsin; Türkmen, Esma; Öztürk, Türkan; Özçelik, Melike; Çabuk, Devrim; Sevinç, AlperBackground: Prognostic factors and the standard treatment approach for gynaecological carcinosarco-mas have not yet been clearly defined. Although car-cinosarcomas are more aggressive than pure epithelial tumours, they are treated similarly. Serous/clear cell and endometrioid components may be predictive fac-tors for the efficacy of adjuvant chemotherapy (CT) or radiotherapy (RT) or RT in patients with uterine and ovarian carcinosarcomas. Heterologous carcino-sarcomas may benefit more from adjuvant CT.Aims: We aimed to define the prognostic and predic-tive factors associated with treatment options in ovar-ian (OCS) and uterine carcinosarcoma (UCS).Study Design: Retrospective cross-sectional studyMethods: We retrospectively reviewed the medical re-cords of patients with ovarian and uterine carcinosar-coma from 2000 to 2013, and 127 women were includ-ed in this study (24 ovarian and 103 uterine). Patients admitted to seventeen oncology centres in Turkey be-tween 2000 and December 2013 with a histologically proven diagnosis of uterine carcinosarcoma with FIGO 2009 stage I-III and patients with sufficient data ob-tained from well-kept medical records were included in this study. Stage IV tumours were excluded. The pa-tient records were retrospectively reviewed. Data from 104 patients were evaluated for this study.Results: Age (>=70 years) was a poor prognostic factor for UCS (p=0.036). Pelvic±para aortic lymph node dis-section did not affect overall survival (OS) (p=0.35). Macroscopic residual disease was related with OS (p<0.01). The median OS was significantly longer in stage I-II patients than stage III patients (p=0.03). Adjuvant treatment improved OS (p=0.013). Adju-vant radiotherapy tended to increase the median OSÖğe A small cell carcinoma in the testis associated with testicular teratoma(2014) Türkmen, Esma; Erdoğan, Bülent; Kodaz, Hilmi; Uzunoğlu, Sernaz[Abtract Not Available]Öğe Effect of delayed radical cystectomy for invasive bladder tumors on lymph node positivity, cancer-specific survival and total survival(Sage Publicatıons Ltd., 2018) Turk, Hakan; Un, Sitki; Cinkaya, Ahmet; Kodaz, Hilmi; Parvizi, Murtaza; Zorlu, FerruhIntroduction: Radical cystectomy (RC) is the main treatment option for patients with muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC), which carry the highest risk of progression. In this study, we investigated the effect of time from transurethral resection of the bladder (TUR-B) to cystectomy on lymph node positivity, cancer-specific survival and overall survival in patients with MIBC. Methods: The records were reviewed of 530 consecutive patients who had RC and pelvic lymphadenectomy procedures with curative intent performed by selected surgeons between May 2005 and April 2016. Our analysis included only patients with transitional cell carcinoma of the bladder; we excluded 23 patients with other types of tumor histology. Results: Patients who underwent delayed RC were compared with patients who were treated with early RC; both groups were similar in terms of age, gender, T stage, tumor grade, tumor differentiation, lymph node status and metastasis status. However, when both groups were compared for disease-free survival and overall survival, patients of the early-RC group had a greater advantage. Conclusions: The optimal time between the last TUR-B and RC is still controversial. A reasonable time for preoperative preparation can be allowed, but long delays, especially those exceeding 3 months, can lead to unfavorable outcomes in cancer control.
